KEY PRODUCTS
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
01 1Seqens
01 1FLUTICASONE PROPIONATE
01 1France
01 1Active
01 1Complete
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
GDUFA
DMF Review : Complete
Rev. Date : 2014-05-23
Pay. Date : 2014-05-05
DMF Number : 15456
Submission : 2001-05-24
Status : Active
Type : II
20
Wavelength Enterprises Ltd, based in France, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
One of their notable products is FLUTICASONE PROPIONATE, with a corresponding US DMF Number 15456.
Remarkably, this DMF maintains an Active status since its submission on May 24, 2001, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of May 23, 2014, and payment made on May 05, 2014, indicating their dedication to facilitating drug approvals, Categorized as Type II
